Gastric carcinoids after long-term use of a proton pump inhibitor

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 7, 2012, Pages 644-649

  Jianu, C S ^a,b   Fossmark, R ^a,b   Viset, T ^a   Qvigstad, G ^a,b   Sordal O ^b   Marvik R ^a   Waldum, H L ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; ESOMEPRAZOLE; GASTRIN; LANSOPRAZOLE; OCTREOTIDE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURGERY; CASE REPORT; CELL DENSITY; CELL HYPERPLASIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; ENTEROCHROMAFFIN LIKE CELL; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERGASTRINEMIA; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MALE; MEDICAL HISTORY; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STOMACH CARCINOID; STOMACH PH; STOMACH SCINTISCANNING; TREATMENT DURATION; TUMOR LOCALIZATION; TUMOR REGRESSION;

AGED; BIOPSY; CARCINOID TUMOR; ENTEROCHROMAFFIN-LIKE CELLS; FEMALE; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS; TIME FACTORS;

EID: 84866234607     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12012     Document Type: Article

References (23)

1. Hakanson R, ed. Gastric endocrine cell typing at the light microscopic level. Amsterdam: Elsevier, 1991.
2. Gustafsson BI, Bakke I, Hauso O, et al,. Parietal cell activation by arborization of ECL cell cytoplasmic projections is likely the mechanism for histamine induced secretion of hydrochloric acid. Scand J Gastroenterol 2011; 46: 531-7.
3. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E,. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994-1006.
4. Modlin IM, Lye KD, Kidd M,. Carcinoid tumors of the stomach. Surg Oncol 2003; 12: 153-72.
5. Qvigstad G, Falkmer S, Westre B, Waldum HL,. Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomas" ). Apmis 1999; 107: 1085-92.
6. Larsson H, Carlsson E, Mattsson H, et al,. Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986; 90: 391-9.
7. Bakke I, Qvigstad G, Brenna E, Sandvik AK, Waldum HL,. Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand 2000; 169: 29-37.
8. Cadiot G, Lehy T, Mignon M,. Gastric endocrine cell proliferation and fundic argyrophil carcinoid tumors in patients with the Zollinger-Ellison syndrome. Acta Oncol 1993; 32: 135-40.
9. Solcia E, Capella C, Fiocca R, Rindi G, Rosai J,. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990; 14: 503-13.
10. Havu N,. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986; 35 (Suppl. 1): 42-55.
11. Poynter D, Pick CR, Harcourt RA, et al,. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut 1985; 26: 1284-95.
12. Fossmark R, Martinsen TC, Bakkelund KE, Kawase S, Waldum HL,. ECL-cell derived gastric cancer in male cotton rats dosed with the H2-blocker loxtidine. Cancer Res 2004; 64: 3687-93.
13. Dawson R, Manson JM,. Omeprazole in oesophageal reflux disease. Lancet 2000; 356: 1770-1.
14. Haga Y, Nakatsura T, Shibata Y, et al,. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci 1998; 43: 253-7.
15. Jianu CS, Lange OJ, Viset T, et al,. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012; 47: 64-7.
16. Food and Drug Administration. FDA Background. Omeprazole Magensium (Prilosec 1 TM) Astra Zeneca with Proctor and Gamble. For the Joint Meeting of the Nonprescription Drugs Advisory Committee and the Gastrointestinal Drugs Advisory Committee On October 20, 2000.
17. Fossmark R, Sørdal O, Jianu C, Qvigstad G, Boyce M, Waldum H,. YF476, a gastrin receptor antagonist, causes regression of tumors and normalizes serum chromogranin A in patients with type 1 gastric carcinoids. 9th Annual ENETS Conferance for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; Copenhagen; Denmark 2012.
18. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW,. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992; 102: 1409-18.
19. Waldum HL, Brenna E, Sandvik AK,. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf 2002; 1: 29-38.
20. Brunner G, Athmann C, Schneider A,. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 34-7.
21. Pounder RE, Sharma BK, Walt RP,. Twenty-four hour intragastric acidity during treatment with oral omeprazole. Scand J Gastroenterol Suppl 1986; 118: 108-17.
22. Oksanen A, Sipponen P, Karttunen R, et al,. Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. Gut 2000; 46: 460-3.
23. Sato Y, Iwafuchi M, Ueki J, et al,. Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection. Dig Dis Sci 2002; 47: 579-85.